EHA 2020 | Edition virtuelle

Communication orales LYSA EHA 2020
C Herbaux

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA


S Le Gouill

Ibrutinib, Venetoclax plus Obinutuzumab in newly diagnosed Mantle Cell Lymphoma Patients